The study shows that plasma testing using cfDNA is a less invasive and rapid alternative to confirm the presence of BRAF mutations versus tumor biopsies, and may help in the early identification of patients who are more likely to benefit from treatment with BRAF inhibitors. Here, BRAF is linked to neoplasm.